Market Closed -
Nasdaq
01:30:00 27/04/2024 am IST
|
5-day change
|
1st Jan Change
|
10.78
USD
|
+2.76%
|
|
-6.83%
|
-12.00%
|
Fiscal Period: April |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
396.7
|
194.7
|
607
|
312.4
|
291.5
|
454.8
|
-
|
-
|
Enterprise Value (EV)
1 |
364.7
|
127
|
358
|
146.2
|
142.1
|
236.5
|
350.1
|
454.8
|
P/E ratio
|
-16.7
x
|
-6.65
x
|
-10.3
x
|
-3.79
x
|
-2.56
x
|
-3.55
x
|
-4.51
x
|
-21
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
24.6
x
|
15.3
x
|
-
|
-
|
-
|
-
|
27.6
x
|
3.88
x
|
EV / Revenue
|
22.6
x
|
10
x
|
-
|
-
|
-
|
-
|
21.2
x
|
3.88
x
|
EV / EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EV / FCF
|
-
|
-4.52
x
|
-7.29
x
|
-1.85
x
|
-1.86
x
|
-1.71
x
|
-3.41
x
|
-12.4
x
|
FCF Yield
|
-
|
-22.1%
|
-13.7%
|
-54.1%
|
-53.8%
|
-58.3%
|
-29.3%
|
-8.08%
|
Price to Book
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
17,247
|
17,846
|
24,308
|
24,543
|
34,169
|
42,188
|
-
|
-
|
Reference price
2 |
23.00
|
10.91
|
24.97
|
12.73
|
8.530
|
10.78
|
10.78
|
10.78
|
Announcement Date
|
15/07/19
|
29/06/20
|
13/07/21
|
07/07/22
|
07/07/23
|
-
|
-
|
-
|
Fiscal Period: April |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
16.13
|
12.69
|
-
|
-
|
-
|
-
|
16.49
|
117.3
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-29.82
|
-40.53
|
-57.92
|
-96.61
|
-110.9
|
-126.1
|
-115.2
|
-34.43
|
Operating Margin
|
-184.91%
|
-319.41%
|
-
|
-
|
-
|
-
|
-698.41%
|
-29.36%
|
Earnings before Tax (EBT)
1 |
-20.69
|
-29.24
|
-46.24
|
-82.34
|
-92.91
|
-113.6
|
-105.7
|
-25.34
|
Net income
1 |
-20.82
|
-29.12
|
-46.24
|
-82.34
|
-92.91
|
-114
|
-109.8
|
-26.74
|
Net margin
|
-129.08%
|
-229.44%
|
-
|
-
|
-
|
-
|
-665.69%
|
-22.8%
|
EPS
2 |
-1.380
|
-1.640
|
-2.420
|
-3.360
|
-3.330
|
-3.038
|
-2.388
|
-0.5125
|
Free Cash Flow
1 |
-
|
-28.06
|
-49.12
|
-79.06
|
-76.46
|
-138
|
-102.6
|
-36.74
|
FCF margin
|
-
|
-221.14%
|
-
|
-
|
-
|
-
|
-621.89%
|
-31.33%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
15/07/19
|
29/06/20
|
13/07/21
|
07/07/22
|
07/07/23
|
-
|
-
|
-
|
Fiscal Period: April |
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
2025 Q2
|
2025 Q3
|
2025 Q4
|
---|
Net sales
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
1.206
|
1.809
|
7.267
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-23.6
|
-26.68
|
-26.81
|
-26.32
|
-25.88
|
-26.94
|
-31.73
|
-29.09
|
-29.75
|
-33.15
|
-34.1
|
-34.07
|
-33.96
|
-34.48
|
-28.01
|
Operating Margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-2,816.17%
|
-1,906.1%
|
-385.46%
|
Earnings before Tax (EBT)
1 |
-19.65
|
-22.47
|
-24.11
|
-23.04
|
-22.26
|
-21.3
|
-26.3
|
-25.32
|
-27.65
|
-29.03
|
-31.65
|
-31.31
|
-31.28
|
-31.87
|
-25.49
|
Net income
1 |
-19.65
|
-22.47
|
-24.11
|
-23.04
|
-22.26
|
-21.3
|
-26.3
|
-25.32
|
-27.65
|
-29.03
|
-32.06
|
-31.38
|
-31.36
|
-31.78
|
-27.56
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-2,600.14%
|
-1,757.2%
|
-379.23%
|
EPS
2 |
-0.8000
|
-0.9200
|
-0.9800
|
-0.9400
|
-0.9000
|
-0.7500
|
-0.7700
|
-0.7400
|
-0.8000
|
-0.8400
|
-0.7217
|
-0.6733
|
-0.6700
|
-0.6733
|
-0.5733
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
09/12/21
|
10/03/22
|
07/07/22
|
08/09/22
|
08/12/22
|
09/03/23
|
07/07/23
|
07/09/23
|
07/12/23
|
11/03/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: April |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
32
|
67.7
|
249
|
166
|
149
|
218
|
105
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-
|
-28.1
|
-49.1
|
-79.1
|
-76.5
|
-138
|
-103
|
-36.7
|
ROE (net income / shareholders' equity)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
1 |
1.08
|
0.22
|
0.08
|
0.93
|
1.2
|
0.23
|
0.8
|
0.83
|
Capex / Sales
|
6.7%
|
1.73%
|
-
|
-
|
-
|
-
|
4.83%
|
0.71%
|
Announcement Date
|
15/07/19
|
29/06/20
|
13/07/21
|
07/07/22
|
07/07/23
|
-
|
-
|
-
|
Last Close Price
10.78
USD Average target price
30.6
USD Spread / Average Target +183.86% Consensus |
1st Jan change
|
Capi.
|
---|
| -12.00% | 455M | | -4.66% | 86.13B | | +1.32% | 39.82B | | -19.27% | 30.42B | | +57.86% | 25.23B | | -16.09% | 15.36B | | -9.14% | 11.95B | | -17.69% | 11.6B | | -43.00% | 11.51B | | +5.24% | 8.71B |
Biopharmaceuticals
|